IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0994585
(2001-11-27)
|
발명자
/ 주소 |
|
출원인 / 주소 |
- Transform Pharmaceuticals, Inc.
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
23 인용 특허 :
34 |
초록
▼
The invention concerns arrays comprising hundreds, thousands, to hundreds of thousands of samples and methods for screening thereof. These methods are useful to optimize, select, and discover compounds, compositions, or conditions that prevent, inhibit, induce, modify, or reverse physical-state tran
The invention concerns arrays comprising hundreds, thousands, to hundreds of thousands of samples and methods for screening thereof. These methods are useful to optimize, select, and discover compounds, compositions, or conditions that prevent, inhibit, induce, modify, or reverse physical-state transitions, particularly in-vivo physical-state transitions relating to disease causing processes. Such compounds, compositions, or conditions can be exploited to treat (e.g., reverse) or prevent the disease itself, the cause of the disease, or the symptoms of the disease.
대표청구항
▼
What is claimed is: 1. A method of screening an array of at least 96 samples to identify conditions, compounds, or compositions that inhibit or prevent transitions of physical state comprising: (a) preparing and identifying an array of at least 96 samples in tubes and support plates or in sample we
What is claimed is: 1. A method of screening an array of at least 96 samples to identify conditions, compounds, or compositions that inhibit or prevent transitions of physical state comprising: (a) preparing and identifying an array of at least 96 samples in tubes and support plates or in sample well plates and dispensing a liquid medium, a disease-causing substance comprising crystallized calcium oxalate in liquid form, salts of citric acid and one or more additional components into sample tubes or sample wells with an automated distribution mechanism, and wherein each sample differs with respect to the identity of one or more of the additional components; (b) processing one or more of the samples to induce crystallization, precipitation or deposition of the disease causing substance, said processing comprising the addition of one or more additional components; (c) analyzing the processed samples to detect the induction of said crystallization, precipitation or deposition using polarized light analysis and Raman spectroscopy; and (d) selecting those processed samples that exhibit inhibition or prevention of a transition in physical state. 2. The method of claim 1, comprising the addition of said samples to tubes in a support plate. 3. The method of claim 2, wherein said tubes are glass tubes and said support plate is a metal support plate. 4. The method of claim 1, comprising sealing said tubes with a cap. 5. The method of claim 4, wherein said cap is pierced with a standard syringe needle and fluid aspirated through the syringe tip to remove solvent from the sample. 6. The method of claim 1, wherein said array comprises at least 1000 samples. 7. The method of claim 1, further comprising the generation of a work list for instructing an automated distribution mechanism to prepare said array of samples. 8. The method of claim 1, wherein said sample contains less than 1 milligram of said disease-causing substance. 9. The method of claim 6, comprising the piercing of said cap and aspiration of medium from said samples. 10. The method of claim 1, wherein said one or more of the additional components the is a small molecule. 11. The method of claim 1, wherein said array comprises at least 1 sub-array. 12. The method of claim 1, wherein said array comprises at least 1 sub-array with at least 24 samples. 13. The method of claim 1, wherein the processed samples are analyzed to detect a solid or an absence of a solid. 14. The method of claim 13, wherein a detected solid is analyzed to determine if the solid is amorphous or crystalline. 15. The method of claim 1, wherein at least about 100 samples are screened per day. 16. The method of claim 1, wherein at least about 1000 samples are screened per day. 17. The method of claim 1, wherein said array comprises sub-arrays, and wherein an individual sample within a sub-array is subjected to processing methods that are different from the processing methods to which another sample within the sub-array is subjected. 18. The method of claim 17, wherein said individual sample is subjected to processing methods comprising adding one or more additional components. 19. The method of claim 1, wherein said array comprises sub-arrays, and wherein an individual sub-array is subjected to processing methods that are different from the processing methods to which another sub-array is subjected. 20. The method of claim 19, wherein said individual sub-array is subjected to processing methods comprising adding one or more additional components. 21. The method of claim 1, wherein the amount of said disease-causing substance in each sample is less than about 1 milligram. 22. The method of claim 1, wherein the amount of said disease-causing substance in each sample is less than about 100 micrograms. 23. The method of claim 1, wherein the amount of said disease-causing substance in each sample is less than about 100 nanograms. 24. The method of claim 1, wherein each sample has a total volume between 5-500 μl. 25. The method of claim 1, wherein each sample has a total volume between 10-200 μl.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.